Angio News and Research

RSS

CHOP researchers unlock 3D structure of crucial protein for cancer therapy

Chimeric Antigen Receptors (CARs) have opened up an exciting new field of therapeutic advancements for rare and difficult-to-treat cancers, as they have the ability to deliver targeted therapies that can kill tumor cells.

1 Dec 2023

Study sheds light on potential mechanism by which psoriasis increases cardiovascular risk

In the largest study to date exploring the relationship between severe psoriasis and coronary microvascular dysfunction, researchers have found further evidence that patients with severe psoriasis are at higher cardiovascular risk.

20 Sep 2023

CHOP helps launch new computational platform to harmonize pediatric cancer data

Children's Hospital of Philadelphia has helped launch a new computational platform that will harmonize pediatric cancer data, allowing researchers, pharmaceutical companies, and advocacy groups to accelerate the pace of drug development for pediatric cancer.

4 Aug 2022

Study shows significant increase in survival rates of extremely pre-term babies

A new study co-authored by a University of Rochester Medical Center researcher has found that the survival rates of extremely pre-term babies has increased significantly in the past decade.

1 Apr 2022

Potential tumor vulnerability may be exploited to improve treatment of neuroblastoma

A Ludwig Cancer Research study has identified a potential vulnerability in neuroblastoma tumors that might be exploited to improve treatment of the aggressive childhood cancer, which accounts for roughly 15% of all deaths from pediatric malignancies.

7 Feb 2022

Study connects hyperglycemia and prolonged cloth mask use to COVID-19-associated mucormycosis risk

A new study conducted in India identifies the role of high blood sugar levels in predisposing patients to mucormycosis infection.

1 Aug 2021

New filling method to treat cerebral aneurysms

Cerebral aneurysms are malformations caused by abnormalities on the walls of blood vessels in the brain. When these blood vessels rupture, about 30% of the sufferers die on the spot, giving these the rightful label of 'ticking bombs in the head'.

10 May 2021

Scientists harness cancer immunotherapy tools to identify targets for COVID-19 vaccine

Cancer researchers at Children's Hospital of Philadelphia have harnessed tools used for the development of cancer immunotherapies and adapted them to identify regions of the SARS-CoV-2 virus to target with a vaccine, employing the same approach used to elicit an immune response against cancer cells to stimulate an immune response against the virus.

8 Jun 2020

Researchers reveal how certain nerves sustain prostate cancer growth

In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels to proliferate.

20 Oct 2017

Innovation in stroke aftercare across Europe: an interview with Professor Urs Fischer

Stroke is the epidemic disease of the twenty-first century and the second most frequent cause of death in 2011, accounting for 11% of all deaths worldwide. Stroke is also the second most important cause of permanent disability and...

13 Dec 2016

Invasive imaging technique can help achieve better outcomes in patients undergoing PCI

An invasive imaging technique called optical coherence tomography (OCT) can visualize the coronary arteries in patients undergoing percutaneous coronary intervention (PCI) and lead to better outcomes compared to standard angiography-guided PCI, according to new findings reported here.

29 Aug 2016

Therapeutic stem cells exit bloodstream in different way than previously thought

Researchers at North Carolina State University have discovered that therapeutic stem cells exit the bloodstream in a different manner than was previously thought. This process, dubbed angiopellosis by the researchers, has implications for improving our understanding of not only intravenous stem cell therapies, but also metastatic cancers.

29 Jun 2016

MESA announces acquisition of Sigil

MESA Group Holdings, a Pantheon Healthcare Group company, today announced the acquisition of French diagnostic imaging service provider Sigil. Complementing MESA's recent business expansion into France with its core Multi-Vendor Service (MVS) and Managed Equipment Service (MES) offerings, the acquisition of Sigil will accelerate the development and adoption of more efficient asset management and medical equipment maintenance service solutions for public and private sector hospitals and imaging centres.

22 Jun 2015

IMRIS announces net loss of $6.8 million for fourth quarter 2014

IMRIS Inc. today reported financial results for the fourth quarter and full year ended December 31, 2014. All figures are reported in U.S. dollars. The Company's net loss in the 2014 fourth quarter was $6.8 million, or $0.13 per diluted share, on net revenues of $9.6 million.

4 Mar 2015

IMRIS closes private placement offering of 10,563,380 units

IMRIS Inc. today announced it has closed the private placement offering of 10,563,380 units at an offering price of US$0.284 per unit.

25 Dec 2014

IMRIS successfully completes human factors study for SYMBIS Surgical System

IMRIS Inc. today announced that the Company has successfully completed the human factors study for the SYMBIS Surgical System – the comprehensive validation used to support the product's 510(k) submission to the U.S. Food and Drug Administration on November 26.

1 Dec 2014

IMRIS enters into Waiver and Amendment Agreement with Deerfield Management Company

IMRIS Inc. ("IMRIS" or the "Company") today announced it has entered into a Waiver and Amendment Agreement with Deerfield Management Company, L.P. ("Deerfield") with respect to the Facility Agreement dated as of September 16, 2013.

24 Sep 2014

IMRIS receives FDA clearance for new neurosurgical HFD rocker arm

IMRIS Inc. today announced a new rocker arm accessory that expands choices for neurosurgeons to select the best fixation suited for patients during procedures using intraoperative imaging inside the VISIUS Surgical Theatre. The accessory recently received 510(k) clearance from the U.S. Food and Drug Administration.

11 Sep 2014

Use of VISIUS iMRI in brain tumor surgery results in complete tumor removal

IMRIS Inc. today announced that a recently published article in the journal Neurosurgery is the highest level clinical evidence to show that the use of VISIUS® intraoperative MRI in brain tumor surgery results in complete tumor removal in more patients with glioma tumors.

26 Aug 2014

IMRIS receives licensing to incorporate MRI core technology into VISIUS Surgical Theatre in Canada

IMRIS Inc. today announced that the Company has received Health Canada licensing to incorporate next generation MRI core technology into the VISIUS Surgical Theatre for sales and marketing in the country.

22 Aug 2014